Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PNEUMOVAX 23 Revaccination in Older Adults
NCT00560950Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Primary completion
- May 2008
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jul 2007; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00560950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560950.